Credit: CC0 Public Domain
A multi-state study published in The Lancet is one of the first real-world data analyzes of the effectiveness of the RSV (respiratory syncytial virus) vaccine. VISION Network researchers found that during the 2023-2024 respiratory disease season, the first season since RSV vaccines were approved in the United States, these vaccines will be effective in older adults, including those who are immunocompromised. They reported that it was generally very effective.
RSV vaccination is approximately 80% effective in preventing severe illness, hospitalization, intensive care unit admission and death due to respiratory infections, and is also effective in preventing severe illness, hospitalization, and death due to respiratory infections. It had a similar protective effect against mild illness in adults over 60 who did not. older. Within this population, people aged 75 and older were at highest risk of severe disease and most likely to be hospitalized.
The study is a collaboration between the Centers for Disease Control and Prevention (CDC) and research centers that integrate medical, testing, and vaccination records from the geographically diverse U.S. health care system, all members of CDC’s VISION network. This was conducted as a joint research project.
“Unlike this data study, RSV vaccine clinical trials have been underpowered to assess the vaccine’s effectiveness against severe disease requiring hospitalization. By addressing this evidence gap, We were able to harness the power of big data to determine the effectiveness of the RSV vaccine, information that should inform vaccine policy,” said study co-author Sean Grannis, MD, MSc.
“As a data scientist and a family physician, I encourage older adults to follow CDC guidance and get vaccinated against RSV this and every year for respiratory disease season.”
Dr. Grannis is Associate Director of Data and Analytics at the Regenstrief Institute and Professor of Family Medicine at Indiana University School of Medicine.
In the United States, respiratory disease season typically begins in late September or early October and lasts until March or early April.
RSV affects the nose, throat, and lungs and causes serious illness and death in older adults during seasonal outbreaks. According to the CDC, an estimated 60,000 to 160,000 RSV-related hospitalizations and 6,000 to 10,000 RSV-related deaths occurred annually among U.S. adults age 65 and older in the years before the RSV vaccine was available. I was doing it.
“No vaccine exists that is 100% effective. A vaccine efficacy rate of 80% is very impressive and higher than what we see with influenza vaccines, for example,” said study co-author Brian Dixon, Ph.D., MPA. .
“In short, using real-world data from electronic health records routinely collected in the care of a wide range of people, we show that vaccination is highly effective against hospitalization, severe illness, and death. I found out something.”
Dr. Dixon is interim director and research scientist of the Clem McDonald Center for Biomedical Information at the Regenstrief Institute and a professor at the Indiana University Indianapolis Fairbanks School of Public Health.
Dr. Dixon continued, “Studies like this are critical to understanding the effectiveness of prevention techniques such as vaccination. The annual cost of RSV hospitalizations in adults in the United States is estimated to be between $1.2 billion and $5 billion. “Up to 80% of hospitalizations can be prevented.” This can lead to significant savings for consumers and health systems. ”
VISION facilities participating in this study were Permanente Northwest (Oregon and Washington), University of Colorado (Colorado), Intermountain Healthcare (Utah), Regenstrief Institute (Indiana), and HealthPartners (Minnesota). and Wisconsin), and Kaiser Permanente Northern California (California). , representing 230 hospitals and 245 emergency departments.
Regenstrief will contribute data and scientific expertise to the VISION Network.
Further information: Efficacy of RSV vaccines against RSV-related hospitalizations and emergency department encounters in adults 60 years and older in the United States, October 2023 to March 2024: A test-negative design analysis, The Lancet (2024) www. thelancet.com/journals/lan … (24)01738-0/fulltext
Provided by Legend Leaf Institute
Citation: Study finds RSV vaccine highly effective at protecting older adults from severe illness, hospitalization and death (October 17, 2024) https://medicalxpress.com/news/2024 -10-rsv-vaccine-highly- Retrieved October 17, 2024 effective-old.html
This document is subject to copyright. No part may be reproduced without written permission, except in fair dealing for personal study or research purposes. Content is provided for informational purposes only.
